stockrowVir Biotechnology, Inc.
VIRVir Biotechnology, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $68.6 million, down 7.61% from fiscal 2024.
- Revenue
- −178.3%
- EPS
- +51.4%
- Free cash flow
- +36.8%
Quarter to September 2026, against a year earlier
Follow VIR
Alert me
Vir Biotechnology, Inc. (VIR) Current ratio
Vir Biotechnology, Inc.'s current ratio at the end of the quarter to 30 September 2026 was 6.3×, up 0.8× from fiscal 2025 (5.5×). Over the past ten years it has ranged from 3.0× (fiscal 2018) to 16.0× (fiscal 2017); the current reading is higher than 44% of that period. That is above the Biotechnology industry median of 4.7× and above the Healthcare sector median of 3.2×.
Current ratio, annual
Embed this chart
Annual newest first
| Period | Current ratio | Change |
|---|---|---|
| FY2025 | 5.5× | (36.42%) |
| FY2024 | 8.7× | (3.79%) |
| FY2023 | 9.1× | 83.68% |
| FY2022 | 4.9× | 7.63% |
| FY2021 | 4.6× | (41.26%) |
| FY2020 | 7.8× | 14.54% |
| FY2019 | 6.8× | 130.63% |
| FY2018 | 3.0× | (81.55%) |
| FY2017 | 16.0× | — |
Quarterly newest first
| Period | Current ratio | Change |
|---|---|---|
| Sep 2026 | 6.3× | 4.30% |
| Jun 2026 | 6.0× | (15.02%) |
| Mar 2026 | 7.1× | 28.36% |
| Dec 2025 | 5.5× | (23.65%) |
| 26 more quarters | Free account |
Against its own ten years
Current ratio against peers
| Company | Current ratio |
|---|---|
| LKFT Lakefront Biotherapeutics - Sponsored ADR compare | 32.8× |
| NAMS NewAmsterdam Pharma Company N.V. compare | 11.8× |
| IMNM Immunome, Inc. compare | 11.7× |
| TRAX First Tracks Biotherapeutics, Inc. compare | 9.2× |
| REPL Replimune Group, Inc. compare | 7.1× |
| VIR Vir Biotechnology, Inc. | 6.3× |
| RXRX Recursion Pharmaceuticals, Inc. compare | 5.0× |
| ZYME Zymeworks Inc. compare | 3.3× |
| BHVN Biohaven Ltd. compare | 3.1× |
| Biotechnology industry median | 4.7× |
| Healthcare sector median | 3.2× |
| Market median | 1.6× |
What Current ratio is
Current Ratio shows whether a company’s short-term assets are enough to cover the bills and debts it must pay within the next year.
Current Assets (Total) ÷ Current Liabilities (Total)
More on VIR
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- The full statement